التفاصيل البيبلوغرافية
| العنوان: |
The effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial. |
| المؤلفون: |
Cioccari, Luca, Luethi, Nora, Bailey, Michael, Shehabi, Yahya, Howe, Belinda, Messmer, Anna S., Proimos, Helena K., Peck, Leah, Young, Helen, Eastwood, Glenn M., Merz, Tobias M., Takala, Jukka, Jakob, Stephan M., Bellomo, Rinaldo, for the ANZICS Clinical Trials Group and the SPICE III Investigators, Arabi, Yaseen, Bass, Frances, Erickson, Simon, Kadiman, Suhaini, McArthur, Colin |
| المصدر: |
Critical Care; 7/16/2020, Vol. 24 Issue 1, p1-13, 13p |
| مصطلحات موضوعية: |
VASOCONSTRICTORS, INTENSIVE care units, RESEARCH, ANESTHESIA, RESEARCH methodology, RETROSPECTIVE studies, MEDICAL cooperation, EVALUATION research, IMIDAZOLES, ARTIFICIAL respiration, COMPARATIVE studies, SEPTIC shock, PHARMACODYNAMICS |
| مصطلحات جغرافية: |
VICTORIA, SWITZERLAND |
| مستخلص: |
Background: Septic shock is associated with decreased vasopressor responsiveness. Experimental data suggest that central alpha2-agonists like dexmedetomidine (DEX) increase vasopressor responsiveness and reduce catecholamine requirements in septic shock. However, DEX may also cause hypotension and bradycardia. Thus, it remains unclear whether DEX is hemodynamically safe or helpful in this setting.Methods: In this post hoc subgroup analysis of the Sedation Practice in Intensive Care Evaluation (SPICE III) trial, an international randomized trial comparing early sedation with dexmedetomidine to usual care in critically patients receiving mechanical ventilation, we studied patients with septic shock admitted to two tertiary ICUs in Australia and Switzerland. The primary outcome was vasopressor requirements in the first 48 h after randomization, expressed as noradrenaline equivalent dose (NEq [μg/kg/min] = noradrenaline + adrenaline + vasopressin/0.4).Results: Between November 2013 and February 2018, 417 patients were recruited into the SPICE III trial at both sites. Eighty-three patients with septic shock were included in this subgroup analysis. Of these, 44 (53%) received DEX and 39 (47%) usual care. Vasopressor requirements in the first 48 h were similar between the two groups. Median NEq dose was 0.03 [0.01, 0.07] μg/kg/min in the DEX group and 0.04 [0.01, 0.16] μg/kg/min in the usual care group (p = 0.17). However, patients in the DEX group had a lower NEq/MAP ratio, indicating lower vasopressor requirements to maintain the target MAP. Moreover, on adjusted multivariable analysis, higher dexmedetomidine dose was associated with a lower NEq/MAP ratio.Conclusions: In critically ill patients with septic shock, patients in the DEX group received similar vasopressor doses in the first 48 h compared to the usual care group. On multivariable adjusted analysis, dexmedetomidine appeared to be associated with lower vasopressor requirements to maintain the target MAP.Trial Registration: The SPICE III trial was registered at ClinicalTrials.gov ( NCT01728558 ). [ABSTRACT FROM AUTHOR] |
|
Copyright of Critical Care is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder